ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00000944
  Purpose

The purpose of this study is to determine if a combination anti-HIV drug treatment regimen of indinavir plus lamivudine (3TC) plus zidovudine (ZDV) is effective in treating HIV and in reducing the chances of passing HIV from mother to child. This study will also examine if this combination is well tolerated by HIV-positive pregnant women and if a combination of 3TC plus ZDV is safe for newborns.

Previous studies in adults and children have shown that indinavir plus 3TC plus ZDV can reduce the amount of HIV in the blood. Most HIV-positive pregnant women usually take ZDV to treat HIV and to reduce the chances of giving HIV to their babies. The combination of drugs in this study may be more effective than ZDV alone.


Condition Intervention Phase
HIV Infections
Pregnancy
Drug: Indinavir sulfate
Drug: Lamivudine
Drug: Zidovudine
Phase I

MedlinePlus related topics:   AIDS    AIDS Medicines    AIDS and Pregnancy   

Drug Information available for:   Zidovudine    Lamivudine    Indinavir    Indinavir Sulfate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Prevention, Safety Study
Official Title:   A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Indinavir Co-Administered With Lamivudine (3TC) and Zidovudine (ZDV) in HIV-1-Infected Pregnant Women During Gestation and Post Partum, and in Their Infants Post Maternal Dosing

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment:   24

Detailed Description:

Despite the dramatic reduction of perinatal HIV transmission following the administration of ZDV to mothers and infants, new, more effective strategies are needed. An increasing number of women may require combination antiretroviral therapy for their own disease because they may be resistant to ZDV, may have high viral loads, or may have previously transmitted HIV to an infant while on ZDV monotherapy. The initiation of triple combination therapy, including a protease inhibitor indinavir, during gestation may be the most effective in reducing maternal virus load prior to delivery, thereby potentially benefitting both mother and child.

Women:

Antepartum (until active labor): Indinavir plus 3TC plus ZDV. Intrapartum (active labor until cord clamping): 3TC plus ZDV. Postpartum (after cord clamped to 12 weeks): Indinavir plus 3TC plus ZDV.

Infants:

3TC plus ZDV as soon as oral intake is tolerated (preferably within 12 hours of birth) and continuing for 6 weeks.

[AS PER AMENDMENT 1/27/99: For maternal dosing, one Combivir tablet bid can be substituted for the individual formulation of 3TC and ZDV. For mothers who receive Combivir during the antepartum period, Combivir is held during labor and delivery, and the separate formulations of ZDV and 3TC are used. Patients who prematurely discontinue study treatment should continue to be followed on study for the duration of the study.]

  Eligibility
Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria

Women may be eligible for this study if they:

  • Are HIV-positive.
  • Have been pregnant for 14-28 weeks (are in your 1st or 2nd trimester).
  • Have a normal ultrasound exam when they are screened for the study.
  • Are able to drink 6 glasses of water a day throughout the study.
  • Are at least 13 years old (need consent of parent or guardian if under 18).

Exclusion Criteria

Women will not be eligible for this study if they:

  • Cannot take 3TC or ZDV.
  • Have an active opportunistic (HIV-associated) or bacterial infection at study entry.
  • Have chronic diarrhea.
  • Have epilepsy or cancer.
  • Are pregnant with more than 2 children (triplets, etc.)
  • Have risk factors for premature birth, or other problems with their pregnancy.
  • Have any immediate life-threatening illness.
  • Have severe anemia or other illness for which they require blood products.
  • Have a history of chronic liver or kidney disease.
  • Plan to breast-feed.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000944

Locations
United States, California
UCSF / Moffitt Hosp - Pediatric    
      San Francisco, California, United States, 941430105
UCSD Med Ctr / Pediatrics / Clinical Sciences    
      La Jolla, California, United States, 920930672
San Francisco Gen Hosp    
      San Francisco, California, United States, 94110
United States, Florida
Univ of Florida Health Science Ctr / Pediatrics    
      Jacksonville, Florida, United States, 32209
United States, Illinois
Univ of Chicago Children's Hosp    
      Chicago, Illinois, United States, 606371470
United States, Massachusetts
Children's Hosp of Boston    
      Boston, Massachusetts, United States, 021155724
Brigham and Women's Hosp    
      Boston, Massachusetts, United States, 02115
United States, New York
Bellevue Hosp / New York Univ Med Ctr    
      New York, New York, United States, 10016
Columbia Presbyterian Med Ctr    
      New York, New York, United States, 10032
Bronx Municipal Hosp Ctr/Jacobi Med Ctr    
      Bronx, New York, United States, 10461
SUNY Health Sciences Ctr at Syracuse / Pediatrics    
      Syracuse, New York, United States, 13210
Bronx Lebanon Hosp Ctr    
      Bronx, New York, United States, 10457
United States, Texas
Texas Children's Hosp / Baylor Univ    
      Houston, Texas, United States, 77030
Puerto Rico
Univ of Puerto Rico / Univ Children's Hosp AIDS    
      San Juan, Puerto Rico, 009365067

Sponsors and Collaborators

Investigators
Study Chair:     Diana Wara    
Study Chair:     Yvonne Bryson    
Study Chair:     Ruth Tuomala    
  More Information


Click here for more information about Zidovudine  This link exits the ClinicalTrials.gov site
 
Click here for more information about Lamivudine  This link exits the ClinicalTrials.gov site
 
Click here for more information about Indinavir sulfate  This link exits the ClinicalTrials.gov site
 
Haga clic aquí para ver información sobre este ensayo clínico en español.  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   ACTG 358, PACTG 358
First Received:   November 2, 1999
Last Updated:   July 29, 2008
ClinicalTrials.gov Identifier:   NCT00000944
Health Authority:   United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Pregnancy  
Pregnancy Complications, Infectious  
Drug Therapy, Combination  
Zidovudine  
HIV Protease Inhibitors  
Lamivudine
Indinavir
Disease Transmission, Vertical
Anti-HIV Agents

Study placed in the following topic categories:
Sexually Transmitted Diseases, Viral
Pregnancy Complications
Indinavir
Pregnancy Complications, Infectious
Acquired Immunodeficiency Syndrome
Zidovudine
Lamivudine
Immunologic Deficiency Syndromes
Virus Diseases
HIV Seropositivity
HIV Infections
Sexually Transmitted Diseases
Retroviridae Infections

Additional relevant MeSH terms:
Antimetabolites
Anti-Infective Agents
HIV Protease Inhibitors
RNA Virus Infections
Anti-HIV Agents
Slow Virus Diseases
Immune System Diseases
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Infection
Antiviral Agents
Pharmacologic Actions
Protease Inhibitors
Reverse Transcriptase Inhibitors
Anti-Retroviral Agents
Therapeutic Uses
Lentivirus Infections
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers